GlaxoSmithKline is opening a new research and development center in China that will focus on neurogenerative diseases, The Wall Street Journal reported Friday.

The center will be located in Shanghai.

Jingwu Zang, the founding director of the Institute of Health Sciences in that Chinese city, will lead the center, the newspaper said.

For details, see the WSJ link.